Cytokine responses in virus infections: Effects on pathogenesis, recovery and persistence

Current Opinion in Microbiology

Volumn 1, Issue 4, 1998, Pages 411-418

  Estcourt, Marie J ^a   Ramshaw, Ian A ^a   Ramsay, Alistair J ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; VIRUS VACCINE;

BIOLOGICAL MODEL; BIOSYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; REVIEW; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION;

CYTOKINES; HIV INFECTIONS; HIV-1; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTE SUBSETS; VIRAL VACCINES; VIRUS DISEASES;

EID: 0032130204     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(98)80058-1     Document Type: Article

References (55)

1. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 1997, 186:421-432. This study illustrates how different antigens from the same virus might elicit either T helper cell type 1 or type 2 immune responses. The latter are inappropriate for the clearance of infections but are inhibited by virus-specific cytolytic T cell effector activity. See also [21•].
2. Hogan SP, Foster PS, Tan X, Ramsay AJ: Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity. Eur J Immunol 1998, 28:413-423. This paper shows that strong T helper cell type 2 responses inhibit the development of antiviral immunity but are down regulated by interleukin-12 facilitating viral clearance.
3. Tang YW, Graham BS: T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice. J Clin Invest 1997, 99:2183-2191.
4. + T-cell responses in mice homozygous for disruption of the interleukin-4 gene. J Virol 1997, 71:2518-2521.
5. Mo XY, Tripp RA, Sangster MY, Doherty PC: The cytotoxic T-lymphocyte response to Sendai virus is unimpaired in the absence of gamma interferon. J Virol 1997, 71:1906-1910.
6. Moran TM, Isobe H, Fernandez-Sesma A, Schulman JL: Interleukin-4 causes delayed virus clearance in influenza virus-infected mice. J Virol 1996, 70:5230-5235.
7. Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA: Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol 1996, 70:7103-7107.
8. Baumgarth N, Kelso A: Functionally distinct T cells in three compartments of the respiratory tract after influenza virus infection. Eur J Immunol 1996, 26:2189-2197.
9. Baumgarth N, Egerton M, Kelso A: Activated T cells from draining lymph nodes and an effector site differ in their responses to TCR stimulation. J Immunol 1997, 159:1182-1191.
10. Schijns VE, Wierda CM, van Hoeij M, Horzinek MC: Exacerbated viral hepatitis in IFN-gamma receptor-deficient mice is not suppressed by IL-12. J Immunol 1996, 157:815-821.
11. Sarawar SR, Cardin RD, Brooks JW, Mehrpooya M, Hamilton-Easton AM, Mo XY, Doherty PC: Gamma interferon is not essential for recovery from acute infection with murine gammaherpesvirus 68. J Virol 1997, 71:3916-3921.
12. Sethi SK, Bianco A, Allen JT, Knight RA, Spiteri MA: Interferon-gamma (IFN-gamma) down-regulates the rhinovirus-induced expression of intercellular adhesion molecule-1 (ICAM-1) on human airway epithelial cells. Clin Exp Immunol 1997, 110:362-369.
13. + T cells are activated in a virus-specific manner.
14. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, •• Miller JD, Slansky J, Ahmed R: Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998, 8:177-187. These authors, using tetramers of MHC class I molecules containg viral peptides to directly visualise antigen-specific CD8 T cells during acute virus infection, definitively show that the majority of proliferating cells are antigen-specfic.
15. Orange JS, Salazar-Mather TP, Opal SM, Biron CA: Mechanisms for virus-induced liver disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection. J Virol 1997, 71:9248-9258.
16. Ruby J, Bluethmann H, Peschon JJ: Antiviral activity of tumor • necrosis factor (TNF) is medatiated by p55 and p75 TNF receptors. J Exp Med 1997, 186:1591-1596. This paper demonstrates the role of the p75 TNF receptor in antiviral immunity. The functional activity of different TNF receptors might relate to the activity of soluble versus membrane-bound TNF.
17. Lazdins JK, Grell M, Walker MR, Woods-Cook K, Scheurich P, • Pfizenmaier K: Membrane tumor necrosis factor (TNF) induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells. J Exp Med 1997, 185:81-90. This paper demonstrates differing outcomes of TNF receptor binding on virus production and cell death in HIV-infected T cells. The mechanisms involved may be related to the findings reported in [16•].
18. Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV: Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 1997, 99:3025-3033.
19. Cavanaugh VJ, Guidotti LG, Chisari FV: Interleukin-12 inhibits • hepatitis B virus replication in transgenic mice. J Virol 1997, 71:3236-4323. As in previous work from this group, this paper illustrates the importance of Th1 responses and the role of cytokines in controlling hepatitis B virus replication.
20. Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U: CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997, 159:1012-1018.
21. Milich DR, Schodel F, Hughes JL, Jones JE, Peterson DL: The • hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 1997, 71:2192-2201. This paper illustrates the importance of the nature of the antigen in determining the type of immune response elicited. The different cell phenotypes induced may determine whether the virus is cleared or persists. See also [1•].
22. Zeidler R, Eissner G, Meissner P, Uebel S, Tampe R, Lazis S, Hammerschmidt W: Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997, 90:2390-2397.
23. Heise MT, Pollock JL, OqGuin A, Barkon ML, Bormley S, Virgin HV: Murine cytomegalovirus infection inhibits IFN gamma-induced MHC class II expression on macrophages: the role of type I interferon. Virology 1998, 241:331-344.
24. Mauri DN, Reinhard E, Montgomery RI, Kochel KD, Cheung • TC, Yu GL, Ruben S, Murphy M, Eisenberg RJ, Cohen GH et al.: LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry medator. Immunity 1998, 8:21-30. These authors identify LIGHT, a novel member of the TNF superfamily expressed by activated T cells, as a ligand for the herpes virus entry mediator (HVEM) on T cells. They also suggest that the herpes simplex virus glycoprotein D, which plays a critical role in infection by binding HVEM, may thereby modify LIGHT-HVEM signalling as a mechanism of evasion of antiviral immunity.
25. Shisler J, Yang C, Walter B, Ware CF, Gooding LR: The • adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J Virol 1997, 71:8299-8306. This paper demonstrates another mechanism whereby viruses can inhibit host defense mechanisms. Adenoviruses, by down regulated Fas on infected target cells, may inhibit T cell killing mediated by this mechanism.
26. Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, Banks S, • Wang GH, Senkevich TG, Alnemri ES, Moss B et al.: Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Natl Acad Sci USA 1997, 94:1172-1176. This paper described the novel death effector domain-containing herpes virus and poxvirus proteins which may be used by these viruses to evade host immunity by inhibiting apoptosis.
27. Matsumoto M, Hsieh TY, Zhu N, VanArsdale T, Hwang SB, • Jeng KS, Gorbalenya AE, Lo SY, Ou JH, Ware CF, Lai MM: Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol 1997, 71:1301-1309. This study describes a novel core protein of hepatitis C virus with homology to the human lymphotoxin beta receptor which may modulate host immune responses and contribute to persistence of infection.
28. Schreiber M, Sedger L, McFadden G: Distinct domains of M-• T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. J Virol 1997, 71:2171-2181. This paper delineates two mechanisms by which M-T2, the TNF receptor homologue of myxoma virus, can inhibit host antiviral strategies. The intracellular domain of M-T2 inhibits apoptosis of cells infected with myxoma virus whilst the extracellular domain prevents TNF-mediated cell killing.
29. Cohen OJ, Audrey K, Fauci AS: Host factors in the pathogenesis of HIV disease. Immunological Reviews 1997, 159:31-48.
30. + T cell responses associated with control of viremia. Science 1997, 278:1447-1450. The presence of strongly proliferative T helper cell populations which secrete interferon-γ and β-chemokines correlates with low levels of plasma virus in HIV-infected long term nonprogressors.
31. + T cells from human immunodeficiency virus-infected individuals. Blood 1997, 89:3672-3681.
32. Wasik TJ, Jagodzinski PP, Hyjek EM, Wustner J, Trinchieri G, Lischner HW, Kozbor D: Diminished HIV-specific CTL activity is associated with lower type 1 and enhanced type 2 responses to HIV-specific peptides during perinatal HIV infection. J Immunol 1997, 158:6029-6036.
33. Taoufik Y, Lantz O, Wallon C, Charles A, Dussaix E, Delfraissy JF: Human immunodeficiency virus gp120 inhibits interleukin-12 secretion by human monocytes: an indirect interleukin-10-mediated effect. Blood 1997, 89:2842-2848.
34. Brigino E, Haraguchi S, Koutsonikolis A, Cianciolo GJ, Owens U, Good RA, Day NK: Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc Natl Acad Sci USA 1997, 94:3178-3182.
35. Fantuzzi L, Gessani S, Borghi P, Varano B, Conti L, Puddu P, Belardelli F: Induction of interleukin-12 (IL-12) by recombinant glycoprotein gp120 of human immunodeficiency virus type 1 in human monocytes/macrophages: requirement of gamma interferon for IL-12 secretion. J Virol 1996, 70:4121-4124.
36. Agostini C, Trentin L, Sancetta R, Facco M, Tassinari C, Cerutti A, Bortolini M, Milani A, Siviero M, Zambello R, Semenzato G: Interleukin-15 triggers activation and growth of the CD8 T-cell pool in extravascular tissues of patients with acquired immunodeficiency syndrome. Blood 1997, 90:1115-1123.
37. Chehimi J, Marshall JD, Salvucci O, Frank I, Chehimi S, Kawecki S, Bacheller D, Rifat S, Chouaib S: IL-15 enhances immune functions during HIV infection. J Immunol 1997, 158:5978-5987.
38. Naif HM, Li S, Ho-Shon M, Mathijs JM, Williamson P, Cunningham AL: The state of maturation of monocytes into macrophages determines the effects of IL-4 and IL-13 on HIV replication. J Immunol 1997, 158:501-511.
39. Lokensgard JR, Gekker G, Ehrlich LC, Hu S, Chao CC, Peterson PK: Proinflammatory cytokines inhibit HIV-1(SF162) expression in acutely infected human brain cell cultures. J Immunol 1997, 158:2449-2455.
40. + T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood 1996, 87:4959-4966.
41. Gougeon ML, Lecoeur H, Boudet F, Ledru E, Marzabal S, Boullier S, Roue R, Nagata S, Heeney J: Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a T helper 1 phenotype. J Immunol 1997, 158:2964-2976.
42. Wagner L, Yang OO, Garcia-Zepeda EA, Ge Y, Kalams SA, • Walker BD, Pasternack MS, Luster AD: Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 1998, 391:908-911. This paper demonstrates dual actions of cytolytic T cells in killing virus-infected cells and releasing β-chemokines which prevent infection of bystander cells.
43. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, • Gallo RC, DeVico AL: Inhibition of HIV-1 infection by the β-chemokine MDC. Science 1997, 278:695-698. This paper describes the antiviral properties of a novel β-chemokine from macrophages.
44. Price DA, Sewelle AK, Dong T, Tan R, Goulder PJR, Rowland-Jones SL, Philips RE: Antigen-specific relaese of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr Biol 1998, 8:355-358.
45. Amara A, Gall SL, Schwartz O, Salamero J, Montes M, • Loetscher P, Baggiolini M, Virelizier JL, Arenzana-Seisdedos F: HIV coreceptor downregulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997, 186:139-146. These authors illustrate that HIV uses the α-chemokine receptor for entry and that down regulation of this receptor may be important for prevention of infection.
46. Jankovic D, Caspar P, Zweig M, Garcia-Moll M, Showalter SD, Vogel FR, Sher A: Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J Immunol 1997, 159:2409-2417.
47. Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA: Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol 1997, 158:3947-3958.
48. Geissler M, Gesien A, Tokushige K, Wands JR: Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997, 158:1231-1237.
49. Tsuji T, Hamajima K, Fukushima J, Xin KQ, Ishii N, Aoki I, Ishigatsubo Y, Tani K, Kawamoto S, Nitta Y et al.: Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol 1997, 158:4008-4013.
50. Tsuji T, Hamajima K, Ishii N, Aoki I, Fukushima J, Xin KQ, Kawamoto S, Sasaki S, Matsunaga K, Ishigatsubo Y et al.: Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen. Eur J Immunol 1997, 27:782-787.
51. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, Boyer JD, Weiner DB: In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997, 158:816-826.
52. Giavedoni L, Ahmad S, Jones L, Yilma T: Expression of gamma • interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J Virol 1997, 71:866-72. Expression of interferon (IFN)-γ in a recombinant nef-deleted simian immunodeficiency virus (SIV) was shown to result in increased virus attenuation. Following challenge with virulent SIV, virus titres were lower in macaques that had previously received the IFN-γ-expressing SIV than in those which had received the control nef-deleted SIV.
53. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC: Cytokines and immunity to viral infections. Immunol Reviews 1997, 159:119-135.
54. Rolph MS, Ramshaw IA: Recombinant viruses as vaccines and immunological tools. Curr Opin Immunol 1997, 9:517-524.
55. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A: Flexible •• programs of chemokine receptor expression on human polarised T helper 1 and 2 lymphocytes. J Exp Med 1998, 187:875-883. This paper demonstrates that the exposure of highly polarised Th1 and Th2 cells to different cytokines determines the nature of the chemokine receptors which they express. These, in turn, may be important in the control of tissue-specific migration of effector T cells.